Year-end Sale % OFF 
Abstract
Cervical carcinoma is the most prevalent malignancy second only to breast cancer among women worldwide. Since more than 99% of cervical cancers are caused by human papilloma virus (HPV), measurement of HPV (HPV test) was commonly used in screening risk and/or early stage of cervical cancer as well as assessing the efficacies of the treatments that can decrease the incidence of cervical cancer. Many approaches that diagnose HPV infections have been developed, while most of them have distinct shortcomings. We here established a novel immunoassay method in which the pairs of unlabeled DNA probes firstly bind to HPV16 E6 and E7 RNAs to form the DNA-RNA hybrids, and the hybrids will subsequently be identified by S9.6 antibody. The sensitivity of this highly specific method can reach ~0.923 pg/mL and ~0.424 pg/mL of in vitro transcribed HPV16 E6 and E7 RNA, respectively, and reverse transcription and polymerase chain reaction (PCR) amplification were no longer needed. Thus, our immunoassay approaches can precisely reflect the actually viral load that is related to the course of HPV infection. In addition, it has also fast and low cost characteristic feature.
Highlights
Human papilloma virus (HPV), circular double-stranded oncogenous DNA virus, belongs to Papillomaviridae, Alpha-Papillomavirus genera
To detect DNAs of human papilloma virus (HPV) can be approximately classified into three categories: in situ hybridization and DNA sequencing which detect the target nucleic acids directly[13]; signal amplification methods, e.g., branched DNA assays[14], hybrid capture system[15], and cervista HR HPV test[13,17]; and target amplification assays, e.g., Real-Time PCR13,15,16,18–20, and detection of integrated papillomavirus sequences polymerase chain reaction (PCR) (DIPS-PCR)[15,21]
Using pairs of unlabeled DNA probes which can bind different positions of the HPV16 E6 and E7 RNAs, the method reduces the cost of modification, and increases the sensitivity of the assay
Summary
Human papilloma virus (HPV), circular double-stranded oncogenous DNA virus, belongs to Papillomaviridae, Alpha-Papillomavirus genera. The monoclonal antibody S9.6 which was originally generated in mice by immunization with a Φ X174 bacteriophage-derived synthetic DNA–RNA antigen[26,27] was characterized with high specificity and affinity to DNA–RNA hybrids[27,28,29] This method can precisely demonstrate the actual viral load from patient as we can directly measure the RNA translated products that significantly affect the ability of virus invasion. It is a convenient, fast, but low cost approaches along with high sensitivity and specificity
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
